Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revisionBoth sides next revision | ||
mrepo:46draft [06/12/2019 @ 15:10] – [Insight 46] adammoore | mrepo:46draft [09/12/2019 @ 09:39] – adammoore | ||
---|---|---|---|
Line 24: | Line 24: | ||
=== Accessing Insight 46 data === | === Accessing Insight 46 data === | ||
---- | ---- | ||
- | Much of the Insight 46 data collected at the first wave of clinic visits is available via [[skylark: | + | Much of the Insight 46 data collected at the first wave of clinic visits is available via [[skylark: |
* {{apoe.pdf|ApoE status }} | * {{apoe.pdf|ApoE status }} | ||
Line 33: | Line 33: | ||
* {{Medication.pdf|Medication}} usage | * {{Medication.pdf|Medication}} usage | ||
* Cognitive test results - including {{ad8.pdf|ad8}}, | * Cognitive test results - including {{ad8.pdf|ad8}}, | ||
- | * {{Audiometry.pdf|Audiometry}} | + | * {{Audiometry.pdf|Audiometry}} |
\\ \\ | \\ \\ | ||
---- | ---- | ||
- | Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, | + | Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, |